We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+31.56%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.85B
AUM Growth
+$887M
Cap. Flow
+$277M
Cap. Flow %
7.2%
Top 10 Hldgs %
72.18%
Holding
61
New
10
Increased
9
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$140M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$92.7M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$80.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$79.9M
5
TNGX icon
Tango Therapeutics
TNGX
+$40M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$131M
2
SWTX
SpringWorks Therapeutics
SWTX
+$80M
3
RLAY icon
Relay Therapeutics
RLAY
+$35M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$30.2M
5
SLRN
ACELYRIN
SLRN
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
2 Miscellaneous 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$669M 17.37%
11,173,068
+273,209
+3% +$13.9M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$435M 11.28%
7,396,979
+1,648,580
+29% +$92.7M
PRTA icon
3
Prothena Corp
PRTA
$479M
$421M 10.93%
11,584,280
– –
ARVN icon
4
Arvinas
ARVN
$600M
$277M 7.19%
6,726,491
+1,259,428
+23% +$29.4M
LKFT
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$234M 6.08%
5,756,268
– –
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$5.02B
$188M 4.87%
5,991,479
– –
ANAB icon
7
AnaptysBio
ANAB
$1.67B
$161M 4.18%
7,521,024
– –
ZYME icon
8
Zymeworks
ZYME
$2.02B
$140M 3.62%
13,437,473
– –
TNGX icon
9
Tango Therapeutics
TNGX
$3.94B
$132M 3.43%
13,330,736
+4,609,100
+53% +$40M
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$15.9B
$125M 3.24%
1,013,952
+645,541
+175% +$80.6M
ARGX icon
11
argenx
ARGX
$64B
$115M 2.97%
+300,997
New +$140M
XNCR icon
12
Xencor
XNCR
$1.94B
$112M 2.91%
5,282,516
– –
KURA icon
13
Kura Oncology
KURA
$1.13B
$83.5M 2.17%
5,806,871
– –
SRPT icon
14
Sarepta Therapeutics
SRPT
$2.2B
$80.3M 2.09%
+832,907
New +$79.9M
CRNX icon
15
Crinetics Pharmaceuticals
CRNX
$9B
$71.6M 1.86%
2,012,517
+482,254
+32% +$14.8M
MRSN
16
DELISTED
Mersana Therapeutics
MRSN
$44.9M 1.17%
774,588
– –
CNTA
17
DELISTED
Centessa Pharmaceuticals
CNTA
$44.7M 1.16%
5,618,779
– –
IMNM icon
18
Immunome
IMNM
$3.13B
$41.5M 1.08%
+3,879,415
New +$32.3M
EWTX icon
19
Edgewise Therapeutics
EWTX
$4.64B
$38.2M 0.99%
3,493,194
– –
NMRA icon
20
Neumora Therapeutics
NMRA
$261M
$35.3M 0.92%
2,071,450
– –
THRD
21
DELISTED
Third Harmonic Bio
THRD
$34.9M 0.91%
3,182,444
+200,000
+7% +$1.58M
VYGR icon
22
Voyager Therapeutics
VYGR
$218M
$32.5M 0.84%
3,851,507
– –
ALEC icon
23
Alector
ALEC
$261M
$32.4M 0.84%
4,056,548
– –
ORIC icon
24
Oric Pharmaceuticals
ORIC
$1.37B
$31.4M 0.82%
3,418,068
– –
TCRX icon
25
TScan Therapeutics
TCRX
$51.1M
$29.1M 0.76%
5,000,000
– –
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2023 Portfolio in Review

As of Q4 2023, EcoR1 Capital held 61 positions worth $3.85B, up 30% from $2.96B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital deployed $277M of net new capital in Q4 2023, opening 10 new positions and adding to 9 existing holdings. Its largest new stake was argenx: 300,997 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Revolution Medicines, an estimated $131M trimmed.

  • EcoR1 Capital's largest Q4 2023 buy was argenx: 300,997 shares worth $115M.
  • EcoR1 Capital added most to Mirati Therapeutics, Inc. Common Stock in Q4 2023, an estimated $92.7M increase.
  • EcoR1 Capital's biggest Q4 2023 reduction was Revolution Medicines, cutting an estimated $131M.
  • EcoR1 Capital fully exited SpringWorks Therapeutics in Q4 2023, selling an estimated $80M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $3.85B portfolio in Q4 2023.
  • EcoR1 Capital opened 10 new positions and closed 10 in Q4 2023.
  • EcoR1 Capital's portfolio value rose 30% quarter-over-quarter to $3.85B.

Based on EcoR1 Capital's 13F filing for Q4 2023, filed 14 Feb 2024.